Amarin (NASDAQ:AMRN) Releases Earnings Results

Amarin (NASDAQ:AMRN) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.21), Zacks reports. The company had revenue of $45.13 million for the quarter, compared to the consensus estimate of $43.77 million. Amarin had a negative return on equity of 5.46% and a negative net margin of 18.16%.

Here are the key takeaways from Amarin’s conference call:

• We have substantially completed our global restructuring and are on track to achieve the estimated $70 million in annual operating expense savings by June 30, 2026; cash rose to $308 million, the company reported a second consecutive quarter of positive operating cash flow, has no debt, and expects to be cash-flow positive for 2026.
• The new fully partnered international model, anchored by an exclusive Recordati agreement covering 59 European countries through 2039, drove Europe product revenue to $4.9 million in Q1 and more than doubled sequentially as Recordati began Vazkepa sales in 10 countries.
• In the U.S., Vascepa remains the market leader with a 48% share of the IPE category and a 17% increase in branded prescriptions year-over-year, but overall U.S. revenue is under pressure from generic competition and management expects to rely on maintained payer exclusives through the end of 2026.
• Cost of goods sold rose 62% year-over-year—driven by regained U.S. exclusivity and new supply shipments to partners—pressuring gross margins and creating quarter-to-quarter revenue and margin variability that is expected to persist until around Q3 2026.

Amarin Stock Performance

Shares of NASDAQ AMRN traded up $0.11 during trading on Wednesday, hitting $14.07. 260,983 shares of the company traded hands, compared to its average volume of 78,824. The business’s fifty day moving average is $14.77 and its 200 day moving average is $15.39. Amarin has a fifty-two week low of $9.44 and a fifty-two week high of $20.90. The firm has a market capitalization of $292.75 million, a price-to-earnings ratio of -156.11 and a beta of 0.81.

Hedge Funds Weigh In On Amarin

Institutional investors have recently made changes to their positions in the stock. Banque Cantonale Vaudoise acquired a new position in shares of Amarin during the third quarter valued at about $32,000. Headlands Technologies LLC acquired a new stake in shares of Amarin in the 2nd quarter worth about $44,000. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Amarin by 1,816.7% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,750 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 5,450 shares during the last quarter. New York State Common Retirement Fund raised its holdings in shares of Amarin by 56.8% in the 4th quarter. New York State Common Retirement Fund now owns 7,605 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 2,756 shares during the last quarter. Finally, Wells Fargo & Company MN raised its holdings in shares of Amarin by 34.8% in the 4th quarter. Wells Fargo & Company MN now owns 9,254 shares of the biopharmaceutical company’s stock worth $129,000 after acquiring an additional 2,390 shares during the last quarter. Institutional investors and hedge funds own 22.25% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on AMRN shares. Zacks Research raised shares of Amarin from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. Wall Street Zen cut shares of Amarin from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Amarin in a research note on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $12.00.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.